Our knowledge about the genetics of myelodysplastic syndromes (MDS) and related
myeloid disorders has been dramatically improved during the past decade, in which …

Major advances in our understanding of cancer pathogenesis and therapy have come from
efforts to catalog genomic alterations in cancer. A growing number of large-scale genomic …

Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing
factor–encoding genes SF3B1, U2AF1, and SRSF2 that confer an alteration of function …

Hotspot mutations in splicing factor genes have been recently reported at high frequency in
hematological malignancies, suggesting the importance of RNA splicing in cancer. We …

RNA-binding proteins (RBPs) are essential modulators of transcription and translation
frequently dysregulated in cancer. We systematically interrogated RBP dependencies in …

Mutations in several general pre-mRNA splicing factors have been linked to myelodysplastic
syndromes (MDSs) and solid tumors. These mutations have generally been assumed to …

Spliceosome mutations are common in myelodysplastic syndromes (MDS) and acute
myeloid leukaemia (AML), but the oncogenic changes due to these mutations have not been …

Mutations in genes encoding RNA splicing factors were discovered nearly 10 years ago and
are now understood to be among the most recurrent genetic abnormalities in patients with …

Over the past decade there has been increased awareness of the potential role of
alternative splicing in the etiology of cancer. In particular, advances in RNA-Sequencing …

The success of precision oncology—which aims to match the right therapies to the right
patients based on molecular status—is predicated on a robust pipeline of molecular targets …